Nyxoah Announces $95 Million Public Offering of Ordinary Shares
Summary
Nyxoah SA, a medical technology company focused on innovative solutions for Obstructive Sleep Apnea (OSA), announced a proposed underwritten public offering of 55.2 million ordinary shares at a public offering price of $1.72 per share, for aggregate gross proceeds of approximately $95 million. The offering includes a 30-day underwriter option to purchase up to 8.3 million additional shares. Nyxoah's lead product is the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy for OSA.
Why it matters
Nyxoah's offering provides capital to expand commercialization of its hypoglossal neurostimulation therapy for sleep apnea, following FDA approval in August 2025. The proceeds will support US commercial expansion and R&D for system upgrades, positioning the company to compete in the growing neurostimulation-for-sleep market.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial